geneOmbio provides gene based personalized medicine for cardiac patients with reference to dosage of warfarin, clopidogrel and statins. The genetics tests are helpful in understanding the difference in rate of drug metabolism in each patient.
A patient’s CYP2C9 and VKORC1 genotype can be used to help determine the optimal starting dose of warfarin
This test is performed to identify patients who may be at risk for altered metabolism of drugs that are modified by CYP2C19 and to predict the anticoagulation response to clopidogrel.
Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin for the lowest chance of developing myopathy. Efficacy of statins by pharamcogenetic testing can also be assessed.